Edwards Lifesciences Corporation $EW Shares Sold by South Dakota Investment Council

South Dakota Investment Council reduced its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 8.6% during the third quarter, HoldingsChannel reports. The fund owned 57,880 shares of the medical research company’s stock after selling 5,458 shares during the quarter. South Dakota Investment Council’s holdings in Edwards Lifesciences were worth $4,996,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in EW. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $5,318,092,000. Varma Mutual Pension Insurance Co bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $11,168,000. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 50.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company’s stock worth $234,727,000 after buying an additional 906,345 shares in the last quarter. Conway Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $954,000. Finally, Commerce Bank bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $3,121,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $105.17 on Thursday. The company has a fifty day moving average of $91.51 and a 200-day moving average of $86.68. Edwards Lifesciences Corporation has a twelve month low of $74.66 and a twelve month high of $108.00. The firm has a market capitalization of $60.47 billion, a P/E ratio of 35.86, a P/E/G ratio of 2.81 and a beta of 0.85. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The company had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3.01 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 48,900 shares of Edwards Lifesciences stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $103.05, for a total value of $5,039,145.00. Following the transaction, the vice president owned 22,798 shares of the company’s stock, valued at $2,349,333.90. This trade represents a 68.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 53,945 shares of company stock valued at $5,498,306. Insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Rothschild & Co Redburn raised their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Truist Financial set a $113.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, November 4th. Barclays lifted their price target on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. Raymond James Financial boosted their price objective on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, UBS Group raised their target price on Edwards Lifesciences from $110.00 to $118.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $109.88.

Read Our Latest Stock Analysis on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.